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Abstract
We applied a novel application of FLIM-FRET to in situ measurement and quantification of protein interactions to explore
isoform specific differences in Ab-ApoE interaction and ApoE tertiary conformation in senile plaques in human Alzheimer
brain. ApoE3 interacts more closely with Ab than ApoE4, but a greater proportion of Ab molecules within plaques are
decorated with ApoE4 than ApoE3, lending strong support to the hypothesis that isoform specific differences in ApoE are
linked with Ab deposition. We found an increased number of ApoE N-terminal fragments in ApoE4 plaques, consistent with
the observation that ApoE4 is more easily cleaved than ApoE3. In addition, we measured a small but significant isoform
specific difference in ApoE domain interaction. Based on our in situ data, supported by traditional biochemical data, we
propose a pathway by which isoform specific conformational differences increase the level of cleavage at the hinge region
of ApoE4, leading to a loss of ApoE function to mediate clearance of Ab and thereby increase the risk of AD for carriers of
the APOEe4 allele.
Citation: Jones PB, Adams KW, Rozkalne A, Spires-Jones TL, Hshieh TT, et al. (2011) Apolipoprotein E: Isoform Specific Differences in Tertiary Structure and
Interaction with Amyloid-b in Human Alzheimer Brain. PLoS ONE 6(1): e14586. doi:10.1371/journal.pone.0014586
Editor: Ashley I. Bush, Mental Health Research Institute of Victoria, Australia
Received April 12, 2010; Accepted January 2, 2011; Published January 31, 2011
Copyright:  2011 Jones et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health (NIH) grants AG026240, AG005134, K99 AG033670-01A1, and DK048549 (www.nih.gov). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bhyman@partners.org
Introduction
Inheritance of the Apolipoprotein E (APOE) e4 allele is the
strongest known genetic risk factor for late onset Alzheimer disease
(AD). Compared to the more common APOEe3 genotype,
homozygous APOEe4 carriers have a ,10 fold increased risk
[1,2,3]. Despite the fact that APOEe3 has an allele frequency of
70–80% compared to only 15–20% for APOEe4 [4], approx-
imately 40–65% of AD patients have at least one copy of APOEe4
[5,6].
Apolipoprotein E (ApoE) is a polymorphic protein with 299
residues (Mr=34000) [7]. The three common isoforms ApoE2,
E3, and E4 differ by only two amino acid residues at positions 112
and 158 [8]. ApoE3 and ApoE4 associate with different lipid
particles in plasma and appear to adopt different tertiary structures
as a result of an Arg61-Glu255 salt bridge, which is altered by the
presence of Arg112 in ApoE4. There are two major functional
domains, the N-terminal domain (NT), contains the major
receptor binding region, the C-terminal domain (CT), contains
the lipid binding region, which is also thought to bind Ab [9,10].
The two are connected by a flexible hinge region.
The mechanism by which ApoE isoform affects risk of AD is
uncertain, with roles proposed in all three of the major
pathological hallmarks: Cell death [11], neurofibrillary tangles
[12,13] and senile plaques [3,14]. Studies in vivo show that ApoE4
is associated with increased amyloid deposition in the brain
[14,15], and ApoE protein decorates senile plaques [16]. In vitro
experiments have shown that there are isoform specific differential
interactions of ApoE with Ab, [17,18,19] but it is uncertain
whether this is true in the brain because 1. senile plaque structure
likely differs from synthetic Ab fibrils and 2. the lipidation status of
ApoE associated with plaques, and possible post-translational
modifications including cleavage, are difficult to model in vitro.
Computation biophysics work recently published by the Paralvrez-
Marin group in Sweden [20] has shown that ApoE4 is expected to
have a pathological stable intermediary conformation that is
mediated by the inter-domain interaction. In addition, there is
evidence that ApoE4 is more susceptible to proteolytic cleavage
than ApoE3 [21].
The hypothesis that ApoE isoforms adopt different structures in
the context of AD pathology therefore remains open (for reviews;
see [22,23,24]). A potentially useful method for such measure-
ments would be fluorescence lifetime imaging microscopy (FLIM)
[25], making use of Fo ¨rster resonance energy transfer (FRET) [26]
to measure the closeness of two protein epitopes. FLIM-FRET
makes use of the characteristic fluorescent decay profile of a
fluorophore, in particular, its lifetime (t). When a higher energy
(more blue) flourophore (donor) is placed in very close proximity
(,1–10 nm) to a lower energy (more red) fluorophore (acceptor)
whereby the emission profile of the donor overlaps with the
excitation profile of the acceptor, the donor fluorophore will lose
energy to the acceptor resulting in a dimming and shortening of
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donor with ultra-high temporal resolution (<80ps), it is possible to
calculate both the percentage of donor molecules that are
interacting with acceptors and the distance between the interacting
molecules. Until recently, this technique has proved challenging
for in situ measurements due to contamination of the signal with
background tissue autofluorescence. In order to perform FLIM-
FRET measurements in situ, we have previously developed a suite
of analysis techniques [27] called x
2 filtering and multiple
Gaussian fitting for lifetime evaluation (MUGLE). The consider-
ation of interacting fraction and FRET efficiency as separate
parameters is vital to the interpretation of FLIM data, especially
with regards to immunohistochemical stains. FRET efficiency is
not subject to confounds of differences in labeling efficiency,
provided interacting fraction is considered separately.
We reasoned that if ApoE isoforms differentially interact with
Ab in senile plaques, we may be able to detect, using advanced
imaging techniques that are sensitive to protein conformation,
distinct conformational patterns of ApoE3 and ApoE4, when
associated with senile plaques. These analyses found both
differences in conformation between ApoE3 and ApoE4, and also
evidence for differences in post-translational modification (cleav-
age) between ApoE3 and ApoE4 protein associated with plaques,
which were confirmed with standard biochemical analyses.
Results
We conducted a series of FLIM-FRET experiments using
human postmortem tissue sections obtained from the Massachu-
setts Alzheimer Disease Research Center (ADRC) brain bank
(table 1) to examine ApoE conformation when it is associated with
senile plaques in situ in the Alzheimer brain (figure 1). The sections
from individuals were homozygous for either APOEe3 or APOEe4
genotype and all had a diagnoses of AD confirmed at autopsy.
Initially, Ab was immunolabeled with the donor fluorophore
(A488) using the Ab specific antibody (3D6), and either ApoE CT
or ApoE NT were immunolabeled with Cy3 using terminal
specific antibodies, 3H1 and 6C5 respectively.
To determine the effect to which the proteins were colocalized,
two channel confocal images (figure 1a) were acquired and a
correlation coefficient was calculated based on the pixel wise
correlation of the green and red channels. For all images, strong
correlations were observed (R
2.0.9, p,1e-6), but no difference
was observed in the extent of co-localization of ApoE and Ab
between the isoforms.
As a more informative method of determining the degree of
interaction, FLIM analysis was applied to the data. The advantage
of using FLIM-FRET is that both the proportion of epitopes that
are interacting and the closeness of that interaction can be
independently calculated from the same data set [26], allowing us
to address both the question of propensity to bind and closeness of
interaction, in a well separated fashion. Three epitopes were
labeled in FRET pairs (figure 1b).
Difference in Ab-ApoE distance for each isoform (figure 1c)
reached trend levels in the initial Bonferroni-Dunn post-hoc tests
(p,0.1). If we examine the data by terminal, we see that Ab-ApoE
NT distance is less for ApoE3 than ApoE4 in the (p,0.05), but this
is not the case for Ab-ApoE CT (p=0.125). These data suggest
that the CT of both ApoE3 and ApoE4 interact with Ab in senile
plaques in a similar fashion, but that the NT domains adopt an
isoform specific tertiary structure.
ApoE CT is closer to Ab than ApoE NT for both isoforms.
(p,0.0001: post-hoc test split by isoform; p,0.0005, -ApoE3-,
p,0.0001, -ApoE4-). These data support a model, based on in vitro
Table 1. List of cases used for the FLIM-FRET study.
case # APOE genotype age at death Sex PMI (hrs) ApoE NT, Ab ApoE CT, Ab ApoE CT, NT
1 e3/3 88 F 12 3
2 e3/3 83 F 33
3 e3/3 75 F 33
4 e3/3 88 M ,12 33
5 e3/3 87 F 4 3
6 e3/3 82 M 9 3
7 e3/3 73 F 3
8 e3/3 82 F 7 3
Total number of plaques 20 20 14
9 e4/4 78 F 33 3
10 e4/4 74 M 18 33
11 e4/4 78 M 16 33
12 e4/4 68 F 23 3
13 e4/4 81 M 3
14 e4/4 84 F 3
15 e4/4 84 M 24 3
16 e4/4 80 F 10 3
17 e4/4 3
Total number of plaques 19 25 22
The genotype, age of the patient at death, sex and postmortem interval (PMI) is given where available from ADRC records. The check marks show which of the three
experiments in which the brain was used. Some brains were used in more than one comparison depending on availability of tissue. For each of the 6 comparisons, the
total number of plaques imaged (‘n’) is also given.
doi:10.1371/journal.pone.0014586.t001
ApoE3 vs 4 in Senile Plaques
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terminal of ApoE [9,10].
Comparisons of the interacting fractions (figure 1d) of Ab-
ApoE3 and Ab-ApoE4 for both termini of ApoE show that a
larger number of the Ab molecules interact with ApoE4 than with
ApoE3 (p,0.0001: post-hoc split by termini; p,0.05, -ApoE CT-,
p,0.05, -ApoE NT-). Surprisingly, we also observed a clear and
significant difference in the interacting fraction of Ab-ApoE CT
compared to Ab-ApoE NT (p,0.0001, post-hoc split by isoform;
p,0.01, -ApoE3-, p,0.01, -ApoE4-), raising the intriguing
possibility that some Ab peptides are bound to isolated ApoE C-
terminal fragments (CTFs) or that some N-terminal domains
become hidden from access by the reagents.
To control for the effect of autofluorescence, plaques stained
only with donor fluorophore were subjected to the same analysis;
no significant FLIM signal was observed. While comparison to
plaques in which the acceptor fluorophore is used to stain a non-
interacting, yet co-localized protein would be ideal, there is no
Figure 1. FLIM-FRET study of ApoE conformation and Ab-ApoE interaction reveals multiple aspects of ApoE4 associated plaque
pathology. Inter-epitope distances are normalized to the Fo ¨rster radius. a) A dense core senile plaque from the cortex of a patient homozygous for
ApoEe3. Ab (green) and ApoE NT (red) are extremely well co-localized which illustrates that the plaque is decorated with ApoE. b) Schematic showing
the three FLIM-FRET measurements that were made. We independently measured the interacting fraction and distance between Ab and both ApoE
terminal domains as well between the two ApoE domains. c) ApoE CT is in closer apposition to Ab than ApoE NT, consistent with the assumption that
the hydrophobic lipid binding region interacts with Ab. The difference in distance is small enough to suggest that ApoE envelops Ab in a similar
fashion than it is known to interact with lipids. d) A significantly greater proportion of Ab is bound to ApoE in the case of ApoE4. The data suggest a
reduced capacity of ApoE4 to induce clearance of Ab. e) ApoE4 has a slightly tighter terminal interaction. This is surprising because a large difference
in inter-terminal interaction is expected from the in vitro data. f) ApoE shows a significantly lower numbers of interacting terminal domains. These
data are proof that ApoE4 undergoes a greater amount of cleavage either before or after binding to Ab. Differential cleavage may mediate Ab
clearance or deposition.
doi:10.1371/journal.pone.0014586.g001
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However, we can state that this technique, including choice of
filters and fluorophores is a long standing technique that may be
considered validated. [28]
To directly test the model that ApoE CT binds plaques, and
that ApoE NT are differentially positioned in ApoE3 and ApoE4,
we performed FLIM-FRET experiments comparing the distance
between the two terminal domains of ApoE associated with
plaques. ApoE CT and ApoE NT were immunolabeled with
donor and acceptor fluorophore respectively (figure 1e). A
significant (p,0.05) but small difference in inter-terminal distance
suggests that the N and C termini of ApoE decorating a plaque are
quite close to one another, but that ApoE4 isoform differs from
ApoE3 in that the N and C termini are slightly closer together.
In addition to this subtle difference in C-N termini distance, we
observe that the N and C termini have a much higher interacting
fraction for ApoE3 than ApoE4 (p,0.0001) (figure 1f). This result is
consistent with the isoform specific difference in interacting fraction
observedforApoE-Abinteractions(figure1a),andstronglysupports
the hypothesis that the N-terminal domain of ApoE4 is either
hidden or missing in some ApoE molecules associated with plaques.
To examine whether the observed differences between ApoE3
and ApoE4 were the result of differences in ApoE cleavage in the
brain, or if they are local effects associated with the plaques
themselves, brain samples, taken from the Massachusetts Alzhei-
mer Disease Research Center brain bank were homogenized and
ApoE was characterized using western blot. Samples were selected
to be confirmed AD and homozygous for either APOEe3o r
APOEe4; non-AD control brains (homozygous for APOEe3) were
also sampled. The antibody used was a commercial polyclonal
goat anti-ApoE (Calbiochem, catalog #179478). Figure 2a shows
an exposure that illustrates the differential banding patterns
between genotypes. Densitometry data, which was obtained from
a lower exposure than that shown, were averaged over 3 blots with
‘n’s of 9, 13, and 11 (cognitively normal, AD 3/3, and AD 4/4).
The total concentration of ApoE was found to be significantly
Figure 2. Western blots of brain homogenates from AD patients and normal aged brains. a) Using poly-clonal antibody, the distribution
of ApoE fragments is clearly different between healthy aged brains and AD brains with further marked differences between genotypes. b)
Comparisons of densitometry show significant increases in the amount of ApoE in Alzheimer brains, with the greatest amount in individuals
homozygous for ApoE4. c) We also measured an increase in LMW (7–10 kDa) fragments in the case of AD, the presence of APOEe4 further amplifies
the effect. The effect is similar but less subtle for HMW (17–34 kDa) fragments. In all cases asterisks indicate significance as assessed using ANOVA and
Bonferonni-Dunn post-hoc test.
doi:10.1371/journal.pone.0014586.g002
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APOEe4/4 genotype (p,0.0001 figure 2b).
To investigate degradation and fragmentation, two ranges of
interest of molecular weights were defined. The low molecular
weight (LMW) band between 7–10 kDa; appears among AD
patients with both APOEe3/3 and APOEe4/4, and doesn’t seem
to be present in normal brains. A strong band of fragments
between about 17 and 34 kDa, designated High Molecular Weight
(HMW), is present in all brains but is stronger and broader in AD,
and particularly so in ApoE4, AD brains. Densitometry (figure 2c)
reveals significant differences in the amount of LMW fragments
between normal and AD(4/4) brains and between AD(3/3) and
AD(4/4) brains, with the difference between normal and AD(3/3)
narrowly missing significance, (3 way ANOVA P,0.0001,
Bonferonni-Dunn post-hoc test: control vs AD(3/3), p,0.05;
control vs AD(4/4), p,0.0001; AD(3/3) vs AD(4/4), p,0.0001).
The differences in HMW fragment density were more subtle with
significance detected only between normal and 4/4 (p,0.01).
To separate CTFs and NTFs of ApoE, new samples were
prepared from brains with the greatest proportion of fragments for
both ApoE3 and ApoE4. These samples were probed with
terminal specific antibodies 3H1 and 6C5 (figure 3a). Results were
similar across genotypes in terms of antibody specificity for
fragments. HMW fragments were detected with the anti-CTF and
anti-NTF antibodies, whereas LMW fragments were detected only
with anti-CT antibody. Therefore, the LMW fraction can be
Figure 3. Western blots probing for the termini of ApoE. a) Blots using terminal specific antibodies reveal that the LMW band, and the lower
portion of the HMW band are almost exclusively composed of C-terminal fragments. b) Blots of fractional brain extracts show that some higher
molecular weight fragments exist in the TBS fraction. The Triton fraction contains comparatively few fragments of any size. The bulk of the degraded
ApoE, particularly the LMW band appears in the SDS and formic acid fractions, implying that the degraded C-terminal fragments of ApoE are
associated with amyloid plaques.
doi:10.1371/journal.pone.0014586.g003
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mixture of fragments from both terminal domains.
To discover if the ApoE fragments were soluble in the brain or
associated with aggregated protein, samples were sequentially
homogenized in 5 volumes of pure TBS with protease inhibitor
cocktail, 2% Triton X-100, and 2% SDS, the SDS insoluble pellets
were sonicated in 70% formic acid (see methods). Blots of these
protein fractions (figure 3b) show that there are limited numbers of
HMW soluble ApoE fragments in both APOEe3/3 and APOEe4/
4 brains. Very few fragments were observed in the Triton fraction.
Almost all of the LMW CT fragments were found in the SDS
fraction, confirming that these ApoE fragments are insoluble and
therefore likely to be at least partially aggregated or associated
with senile plaques.
Taken together, these data suggest that ApoE undergoes
isoform specific differential cleavage in the AD brain with
significantly more degradation, particularly of the CTF, for
ApoE4 than ApoE3. We can also say that, consistent with our
FLIM data, isolated CTFs are associated with senile plaques.
Discussion
Inheritance of APOEe4 is known to be associated with
increased risk for AD compared to the more common APOEe3.
The proteins ApoE3 and ApoE4 are known to differ in the
periphery where they associate with low and high density lipids
respectively [29], likely because they adopt different conforma-
tions. In the brain, however, there is only one class of ApoE
containing lipoprotein particle, an HDL-like particle; ApoE is also
associated with Ab deposits in senile plaques. Whether or not
ApoE3 and ApoE4 present different conformations when
associated with senile plaques is unknown. We utilized a new
application of FRET-FLIM to interrogate ApoE-Ab interactions,
and ApoE conformation when associated with plaques in the
Alzheimer brain.
We show that 1. Both isoforms of ApoE interact closely with
fibrillar Ab, but that 2. ApoE3 interacts more closely with Ab
than ApoE4. 3. For both isoforms, the amphipathic C-terminal
interacts most closely with Ab. 4. A greater number of Ab
molecules interact with ApoE4 than with ApoE3. 5. ApoE4
adopts a conformation with slightly shorter CT-NT distance than
ApoE3. 6. Fewer CTs interact with NTs in the case of ApoE4,
indicating a greater level of degradation. 7. Greater amounts of
ApoE can be found in Alzheimer brain than normal brains and
that the effect is most pronounced among APOEe4/4 individuals.
8. In the AD brain ApoE undergoes significantly more cleavage
than in normal brains, and the effect is further amplified amongst
carriers of APOEe4. 9. Isolated CTFs are associated with senile
plaques especially for ApoE4. The major findings of this work are
summarized in a schematic form in figure 4, with the distances
translated into approximate nm units. For this calculation, the
Forster radius of A488 and Cy3 was approximated using the
value for A488, and Alexafluor 555 (70 nm) given on the
Invitrogen website, which has an almost identical excitation
spectrum to Cy3.
FRET has become an established technique for assessing
protein interactions and changes in protein conformation in living
cells and in stained tissue [30]. While it is sometimes said that the
distance over which interactions are measured in FRET are too
great to prove molecular interactions, it is also true that FRET
does not measure the distance between nuclei of bound atoms,
rather the distances measured here, of the order of 5–10 nm, are
entirely reasonable for the detection of distances between two
epitopes on large proteins. It is also the case that while for single
molecule FRET it is conceivable that the FRET signal is due to
happenstance proximity between two molecules, in a real system,
with many molecules, such statistical anomalies are rare and
would not create a significant signal. This point was elegantly
demonstrated in work by Server et al [28], by comparing a
colocalization and FLIM measurement of dynamin-auxilin
interaction for both wild-type and a mutated dynamin whereby
the interaction was disrupted without altering the spatial
distribution of the proteins. It is worth noting however, that this
technique does not tell us about the nature of the interaction, these
molecules may interact either by hydrogen bonding or purely
through hydrostatic bonding. This uncertainty, however, does not
change the interpretation of the data.
These data directly test the hypothesis that an isoform specific
difference in ApoE-Ab interaction can be observed in fibrillar Ab
deposits. Natively lipidated ApoE3 has been shown to have a
greater binding affinity to Ab than ApoE4 [31]. We confirm that
of the two ApoE domains, the ApoE CT is in closer apposition to
Ab, supporting the notion that the C-terminal domain, containing
the major lipid binding region is the region that interacts with Ab,
and that the CT of both ApoE3 and ApoE4 interact closely with
Ab. However, the difference between the two distances is small
enough to suggest that ApoE might encapsulate Ab, in a similar
fashion to the way in which it interacts with lipids [32].
There are however, distinct differences in the nature of the
interaction. Specifically, ApoE3 interacts more closely with Ab in
senile plaques. In addition, a greater number of Ab molecules
interact with ApoE4 than ApoE3. Finally, the ApoE N-terminus
appears to be buried or missing, especially in ApoE4 cases;
biochemical analyses suggest that ApoE undergoes cleavage, again
especially for ApoE4, suggesting that the N-terminus is indeed
separated from the C-terminus in ApoE4 plaques. This interpre-
tation is consistent with the previous studies which indicate that
ApoE4 undergoes more degradation in the AD brain than ApoE3
[33].
There is a well documented conformational difference between
ApoE3 and ApoE4 caused by an interaction between the two
highly structured terminal domains that is stronger in the case of
ApoE4 [4,34]. One consequence of the isoform specific domain
interaction and conformational change may be the relative
vulnerability to cleavage of the unstructured hinge region. If this
were the case, then we postulated that we might detect a
differential likelihood in observing N-C terminal interactions. Our
analysis directly tested this hypothesis and revealed that ApoE4
adopted a slightly tighter conformation with an increased closeness
of N-C terminal interaction. It is surprising that the conforma-
tional difference between the isoforms was comparatively small
compared with expectations based on in vitro data [34,35,36]. It is
worth noting that the effects of ApoE isoform take many decades
to cause an effect in patients, a more drastic effect might be
expected to result in onset of symptoms far earlier, as is observed
in familial AD cases. This result particularly highlights the need for
in situ measurements of endogenous proteins to confirm that
observations made in reduced preparations, like tissue culture or in
solution, can be extended to the native environment.
We also note a greater interacting fraction between the Ab and
ApoE CT, compared with ApoE NT. At the same time, the lower
interacting fraction between the NT and CT of ApoE, especially
for ApoE4, indicates that either the epitope for the N-terminal
specific ApoE antibody has been partially occluded or an
increased number of isolated C-terminal fragments exist in senile
plaques in the case of ApoE4. Since previous biochemical studies
suggest that ApoE4 is cleaved at the hinge region to a greater
extent than ApoE3 [21,37], and that elevated levels of ApoE4
ApoE3 vs 4 in Senile Plaques
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of APOEe4 [37], we tested the possibility that the decreased
interacting fraction that we observed indicates a pathologically
elevated cleavage of ApoE4. Work by Riddell and Zhou [38] in
mice suggests that enhanced degradation of ApoE4 by astrocytes
leads to lower levels of ApoE and thereby impacts clearance, while
recent work from the Garner lab [39] suggests that ApoE3 suffers
greater fragmentation without regards for whether the patient had
AD as assessed in the TBS fraction of human brain. By contrast,
we find increased cleavage in AD, and especially, in ApoE4
individuals, using both biochemical assays and, importantly,
FRET based assays of the protein in situ. Since ApoE contains
an unstructured region and is somewhat prone to aggregation, it is
possible that differences in antibody choice and specificity may
play some role in the differences between observations.
The question remains as to how these observations shape our
understanding as to the differential role of these two isoforms of
ApoE on Ab clearance and deposition. We must consider how
these data fit with the observation that ApoE4 is associated with
greater Ab deposition or clearance of Ab from the neuropil. One
set of hypotheses states that Ab is cleared through the blood brain
barrier to the periphery and ApoE is thought to impede that
process [40], perhaps in an isoform dependant manner. In
addition, ApoE may mediate proteolytic degradation through
neurons, astrocytes or microglial cells [41] by acting as a bridging
protein between Ab and one or more of several candidate
receptors, particularly LRP1 [14] or ApoER2 [42].
The presence of isolated ApoE CT fragments may also
contribute to plaque deposition or stabilization. Our data do not
directly assess ApoE’s role in clearance; instead, however, the
current data demonstrate that ApoE3 and ApoE4 differentially
interact with fibrillar Ab deposits.
These data, taken together lend strong support to the hypothesis
that there is an isoform specific mechanistic effect on plaque
Figure 4. Summary of findings. a) The FLIM-FRET data can be translated into real distances by multiplying by the Forster radius of A488 and
Alexafluor 555 (7 nm). The structural differences between isoforms and interactions with Ab are compared (not to scale but distances marked in nm).
The Ab-ApoE4 distance is larger than Ab-ApoE3 despite the fact that the propensity for interaction is greater. ApoE4 shows a tighter inter-terminal
interaction although the difference is not large. This result suggests that under these conditions ApoE conformation is influenced but not dominated
the domain interaction. Nevertheless, this small conformational difference could lead to a differential vulnerability to cleavage at the hinge region
leading to a larger number of orphan ApoE4 C-terminal fragments bound to Ab. b) Our proposed model for the increased risk of senile plaque
associated with ApoE4. Under normal conditions, ApoE acts as a bridging protein between Ab and one of the lipoprotein receptor proteins, thereby
mediating clearance across the cell membrane. In the Case of ApoE4, the conformational difference leads to enhanced vulnerability to cleavage,
which in turn leads to a loss of clearance function and enhanced deposition.
doi:10.1371/journal.pone.0014586.g004
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correlation between ApoE4 dose and plaque density [13,14] and
strengthens the case for therapeutic intervention targeted at
ApoE4’s unique tertiary structure [43].
Materials and Methods
Tissue and immunostaining
Massachusetts Alzheimer Disease Research Center (ADRC)
Brain Bank provided free floating human brain sections (50 mm)
from patients homozygous for APOEe3 or APOEe4 and with
postmortem confirmed AD.
All sections were pretreated with 10 mM citrate buffer pH6 for
10 minutes at 95uC before immunostaining. Sections were
incubated with either C-terminal specific ApoE antibody, 3H1
(aa 243-272, 1:100, Ottawa Heart Institute); or 3D6, which is
directed against Ab (1:500, Elan Pharmaceuticals) antibodies and
visualized with secondary antibody conjugated to Alexafluor 488
(A488) (Invitrogen). After sequential washing, the sections were
incubated with 6C5 antibody (ApoE NT, aa 1-15, 1:1000) (Ottawa
Heart Institute) directly conjugated to Cyanine 3 (Cy3) (GE
Healthcare). To probe the interaction between Ab and ApoE CT;
Ab was labeled as above and ApoE CT was labeled using 3H1,
directly conjugated to Cy3 [44].
Fluorescence Lifetime Microscopy
Sections were imaged using a Zeiss LSM-510 microscope,
which has excitation and emission channels for confocal, near
infrared and FLIM imaging. Cortical neuritic senile plaques were
initially located using visual inspection of both fluorophores under
epifluorescent wide field microscopy. Upon identification of a
plaque, multi-track confocal images of A488 (green) and Cy3 (red)
were obtained to confirm the co-localization of the two
fluorophores, followed by FLIM imaging. Excitation of A488 for
FLIM was achieved with a picosecond 2-photon laser (Tsunami,
Spectra-Physics). Images were taken with the laser tuned to
760 nm, which we have found to be the most efficient two photon
wavelength for selective excitation of A488 while minimizing
autofluorescent contribution.
Analysis was performed using a combination of SPCImage
v2.9.5 (Becker and Hickl, GmbH) and previously described in
house post analysis programs; x
2 filter and MUGLE [27], written
in MATLAB (Mathworks, MA, USA). In brief, the analysis
method is a multi-stage process. In the first instance, all images
were fit with mono-exponential functions in SPCImage. Matrices
of brightness, lifetime, and goodness of fit parameter (xr
2), are
imported into the program chifilt, in which xr
2 is used as a pseudo-
contrast for autofluorescence. A cutoff for xr
2 is selected by
comparing all images; binary masks are created and saved. A
baseline fluorescent lifetime for the donor fluorophore is obtained
by analyzing the data from sections stained only with donor and
used as a fixed prior lifetime for bi-exponential fits of sections
stained with both donor and acceptor. During both of these later
two stages, pixels are discarded by both the use of a region of
interest around the plaque, and the masks created in the first stage
of analysis. The intensity weighted histogram of the lifetimes is fit
to one or more Gaussians using MUGLE.
Differences in interacting fraction; AF/(AF+ANF), where A is the
pre-exponential factor and the subscripts F and NF refer to the
FRET quenched and unquenched components were calculated
along with normalized inter-terminal distance based on FRET
efficiency
R
R0
~
tNF
tNF{tF
 1=6
{1
where R0 is the Fo ¨rster radius, at which 50% of energy is
transferred from donor to acceptor [26]. Results were analyzed for
significance by analysis of variance (ANOVA) and Bonferoni-
Dunn post hoc tests.
Preparation of Brain extracts
Cortical gray matter from the temporal lobe of AD and non-
demented control patients was homogenized in RIPA lysis buffer
(25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS) containing protease inhibitor cocktail
(Roche, cat #11836153001), and then subjected to centrifugation
at 16,0006g for 20 min at 4uC. The supernatant was used for
SDS-PAGE and Western blot. For fractional brain extracts,
samples were sequentially homogenized in 5 volumes of; TBSI
(Tris-buffered saline containing a protease inhibitor cocktail
[Roche]), 2% Triton X-100, and 2% SDS, with 25 strokes on a
mechanical Dounce homogenizer, and subjected to centrifugation
at 260,0006g for 20 min at 4 degrees for each fractional extract.
In each case, the supernatant was drawn off and used for Western
blot analysis. For the final extraction, SDS insoluble pellets were
sonicated in 70% formic acid, centrifuged at 260,0006g for 30
minutes at 4 degrees. The supernatant was evaporated and
resolubilized in dimethyl dulfoxide (DMSO) for Western blot
analysis.
SDS-PAGE and Western Blot
Protein concentrations were determined by BCA assay. Equal
amounts of total protein were loaded per well and electrophoresed
through 10–20% Tricine or Tris-Glycine gradient gels (Invitrogen,
catalog #E66255BOX and #EE61355BOX) and then transferred
to PVDF membrane (PerkinElmer, catalog #NEF1002001). The
membranes were incubated in blocking buffer (5% nonfat dried
milk in TBS containing 0.01% Tween-20) for 1 h at room
temperature, and then incubated with primary antibody diluted in
blocking buffer for 1–2 h at room temperature. Primary antibodies
used were: goat anti-ApoE (Calbiochem, catalog #179478), 3H1
mouse anti-C-terminal ApoE (Ottawa Heart Institute), and 6C5
mouse anti-N-terminal ApoE (Ottawa Heart Institute). Mem-
branes were then incubated with HRP-conjugated horse anti-goat
(Vector, catalog #PI-9500) or goat anti-mouse (Bio-Rad, catalog
#170-6516) secondary antibody diluted in blocking buffer for 1 h
at room temperature and protein detected by enhanced
chemiluminescence (PerkinElmer, catalog #NEL102001).
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